Adamastor Bioservices and DTI-Tech Announce Strategic Collaboration to Bridge Drug Target Identification and Binding Kinetics Characterisation

Partnership creates an integrated service offering from target discovery through quantitative binding characterisation for pharma and biotech clients

Milan ITALY / Bellinzona, SWITZERLAND — May 28, 2026 — Adamastor Bioservices, a biotechnology company specialising in biophysical binding kinetics, and DTI-Tech, a Swiss company focused on drug target identification through an innovative approach, today announced a strategic collaboration to offer the pharmaceutical and biotechnology industry an integrated service that spans the full path from target identification to quantitative binding characterisation.

The collaboration addresses a longstanding gap in the drug discovery services market. When a bioactive small molecule demonstrates activity against target cells, identifying its protein targets is a critical first step toward understanding its mechanism of action. However, confirming and quantifying how a drug interacts with its identified targets, measuring the speed of association, the rate of dissociation and the binding affinity, requires a different set of biophysical technologies.

Under the new collaboration, DTI-Tech will apply its proprietary DTI-Tech Method and established proteomics approaches to identify the protein targets of client compounds. Adamastor Bioservices will then perform quantitative binding characterisation of confirmed hits using Surface Plasmon Resonance (SPR) and its LigandTracer-based platform to measure real-time binding kinetics in live cells and bacteria.

“While binding kinetics is traditionally leveraged for lead optimization, increasing attention is being directed toward its use in target identification and mechanistic characterization of ligand–target interactions,” said João Encarnação, Founder of Adamastor Bioservices. “By combining DTI-Tech’s proteomics expertise with our biophysical and cellular binding capabilities, we can give clients a single, coherent answer: *here is what your drug binds, and here is exactly how it binds.*”

“In the era of precision medicine, we believe that identifying a novel drug’s target is the most crucial aspect of the drug discovery process.” said Eugenio Gaudio, Co-founder of DTI-Tech. “This collaboration allows us to take the next critical step by providing clients with the quantitative binding data they need to validate targets and drive informed decisions in their drug discovery programmes.”

A distinctive feature of the partnership is Adamastor’s ability to validate drug-target interactions in biologically complex systems. Using LigandTracer technology, binding can be measured in real time on the surface of live cells expressing the identified targets, ensuring that interactions observed in proteomics experiments translate to the native cellular environment with correct post-translational modifications and membrane context.

The collaboration will also extend to protein-protein interaction (PPI) characterisation, mechanism of action elucidation packages, and biophysical support. The two companies plan to co-author scientific publications, develop joint marketing materials, and establish a cross-referral network.

About Adamastor Bioservices

Adamastor Bioservices is an Italian biotechnology company specialising in biophysical binding kinetics for drug discovery and antibody engineering. The company offers expert services in Surface Plasmon Resonance (SPR) and real-time cell-based binding analysis using LigandTracer technology. Adamastor is known for its unique capability to bind to live bacteria and complex biological surfaces, and to integrate biophysical measurements with cellular functional readouts.

About DTI-Tech

DTI-Tech is a Swiss privately held company offering drug target identification services to academia, biotech, and pharmaceutical companies. Founded by experienced cancer researchers Eugenio Gaudio and Francesco Paduano, DTI-Tech employs its proprietary platform to identify drug targets, secondary targets, and pathway modulations during the establishment of drug resistance (typically over 4–8 weeks under continuous drug pressure), with measurements performed weekly. This enables the analysis of acquired protein expression and signaling network adaptations associated with resistance. The approach makes it possible to identify the most effective drug combinations to overcome resistance before it becomes clinically evident in patients. The company also operates an internal drug discovery pipeline focused on oncology.

Media Contacts

Adamastor Bioservices

João Encarnação, Founder

info@adamastor-bioservices.com | +393755953811

DTI-Tech

Eugenio Gaudio, Co-founder

gaudio@dtitech.ch | +41787206609

###